The introduction of targeted therapy represents a major advance in the treatment of tumor
progression. Targeted agents are a novel therapeutic approach developed to disrupt …

Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We …

Abstract Sunitinib malate (SU11248/Sutent; Pfizer) is a multitargeted tyrosine kinase
inhibitor that has potent anti-angiogenic and antitumour activities. Definitive efficacy has …

Sunitinib is an orally available small-molecule multikinase inhibitor. This agent potently
inhibits the vascular endothelial growth factor receptor, platelet-derived growth factor …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent
antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and …

Background The incidence and risk of unique toxicities associated with a multi-targeted
tyrosine kinase inhibitor sunitinib, such as hypertension and thromboembolic events, have …

Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …

Background: Sunitinib was approved by the US Food and Drug Administration (FDA) on
January 26, 2006, for the treatment of metastatic renal cell carcinoma (mRCC) and …

Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma
(RCC), but acquired resistance against targeted therapies remains a major clinical …